$NEO Income Statement | Understand Stock

$NEO

$17.27 +$0.58 (3.48%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
NET REVENUE
Clinical Services
Pharma Services
Advanced Diagnostics
Total nET REVENUE

COST OF REVENUE
Clinical Services
Advanced Diagnostics
Total cOST OF REVENUE
GROSS MARGIN
Clinical Services
Advanced Diagnostics
Total gROSS MARGIN
Operating expenses:
General and administrative
Research and development
Sales and marketing
Restructuring charges
Impairment charges (Note 3 and Note 7)
Total operating expenses
LOSS FROM OPERATIONS
Interest income
Interest expense
Other (income) expense, net
Loss on extinguishment of debt
Loss on termination of cash flow hedge
Gain on investment in and loan receivable from non-consolidated affiliate, net
Loss before taxes
Income tax benefit
NET LOSS
NET LOSS PER SHARE
Basic (in dollars per share)
Diluted (in dollars per share)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic (in shares)
Diluted (in shares)

Comments